Navigation Links
China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013
Date:6/18/2013

085293,832419,50267,544Operating expensesResearch and development

(1,953)(2,249)(362)(7,615)(8,459)(1,362)Sales and marketing

(16,567)(26,116)(4,205)(61,678)(93,684)(15,084)General and administrative

(23,086)(26,992)(4,346)(89,696)(108,045)(17,396)Total operating expenses

(41,606)(55,357)(8,913)(158,989)(210,188)(33,842)Operating income34,84250,7478,172134,843209,31433,702Other income/(expense), netInterest income

3,4114,00264413,43215,0642,425Interest expense

(896)(22,070)(3,553)(3,287)(70,097)(11,286)Exchange gain/(loss)

33(25)(4)(1,343)(984)(158)Dividend income

---7,2174,685754Others

82392414973720333Total other income/(expense), net

3,371(17,169)(2,764)16,756(51,129)(8,232)Income before income tax 38,21333,5785,408151,599158,18525,470Income tax expense

(6,597)(10,483)(1,688)(9,634)(38,543)(6,206)Net income31,61623,0953,720141,965119,64219,264Net income attributable to non-

controlling interests

 

(2,377) 

(67) 

(11) 

(9,985) 

(7,195) 

(1,158)Net income attributable tothe Company29,23923,0283,709131,980112,44718,106Net income per share:Attributable to ordinary shares- Basic

0.400.320.051.791.490.24- Diluted

0.400.320.051.791.490.24Other comprehensive income-
Net effect of foreign currency 
translation, net of nil tax

(604)2,936473(1,653)1,296209-
Net unrealized gain/(loss) in
available-for-sale equity securities,
net of nil tax

58,05512,0231,93646,587(9,120)(1,468)Comprehensive income89,06738,0546,129186,899111,81818,005Comprehensive income attributable
to non-controlling interests

(2,427)(67)(11)(10,282)(7,172)(1,155)Comprehensive income 
attributable to the Company 86,64037,9876,118176,617104,64616,850  

 

 


'/>"/>
SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. RAPS Opens Offices in Singapore and China
2. Research Report on Chinas Diabetes Drug Market, 2013-2017
3. Research Report on Chinas Antidepressant Market, 2013-2017
4. Research Report on Chinas Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017
5. China Cord Blood Corporation to Report Fourth Quarter and Full Year of Fiscal 2013 Financial Results
6. Elsevier Signs Strategic Collaboration Agreement with Peoples Medical Publishing House, China
7. Infinata's BioPharm Insight Global Editor Kim Ha to Moderate Panel at 3rd Annual U.S.-China Conference on Strategies for Mining Profits from Pharma Opportunities in China
8. China Engineering Plastics Industry will Reach US$5 Million By 2017 - Engineering Plastics Market, Share, Size, Analysis, Market Scale, Competition and Forecast 2013-2017
9. China Industry Reports: 2013 Research on Swine Industry Chain, Human Tetanus Immunoglobulin, Power Energy Storage Battery and Wind Power Lubricating Grease at ReportsnReports.com
10. Future Course of New Lethal Avian Flu Outbreak in China Can Be Predicted
11. China Cord Blood Corporation Received AABB Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... CAMBRIDGE, Mass. and REYKJAVIK, Iceland ... provides comprehensive capabilities for using the genome to create better ... publication of the largest studies of whole-genome data yet undertaken. ... Nature Genetics – are built around ... authored by a team of deCODE scientists led by ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 Data ... Novel Mechanism of Action in Neuromuscular Diseases ... – Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication ... muscle troponin activator tirasemtiv in the journal Neurotherapeutics. ... IIa “Evidence of Effect” or hypothesis-generating clinical trial ...
(Date:3/25/2015)... the HAGUE, Netherlands , March 25, ... LES Stimulation therapy for chronic gastro-esophageal reflux disease (GERD) ... [ Surgery . 2015; 157(3):556-567 ], establishing ... therapy. The study included 25 patients ... years and taking prescribed daily proton pump inhibitor (PPI) ...
(Date:3/25/2015)... March 25, 2015  18 piglets born recently ... research by scientists in the College of Agriculture and ... a breakthrough in the field of genetic engineering. ... of Animal & Avian Sciences (ANSC) and Ki-Eun ... successfully produced genome-edited pigs using a recently developed, ...
Breaking Biology Technology:Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3University of Maryland Researchers Successfully Produce Genome-edited Pigs Using Revolutionary Technology 2
... FRANCISCO, CA -- September 6, 2007 -- Researchers at ... College of Medicine have discovered a mechanism by which ... disease. AB, which is known to accumulate in the ... of research into the causes and treatment of the ...
... ThermoGenesis,Corp. (Nasdaq: KOOL ), a leading supplier ... administer therapeutic doses of,adult stem cells for treatment of ... for the fourth quarter and full year ended,June 30, ... Call and Webcast Management will host a conference ...
... in Sales by 2016, According to a ... New Report from Decision Resources, WALTHAM, Mass., ... and advisory firms for pharmaceutical and,healthcare issues, finds that Amgen, the ... billion in 2006, and Genentech,the second leading biologics manufacturer with biologic ...
Cached Biology Technology:Gladstone scientists uncover potential mechanism of memory loss in Alzheimer's disease 2ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007 2ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007 3Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers 2
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... -- In the largest undertaking of its kind, scientists ... a five-year National Institutes of Health (NIH)-funded study to ... the exact causes of hemoglobin toxicity. Hemoglobin in ... can become deadly when cells break open and spill ...
... no scientific evidence that low-level electromagnetic field exposure ... adverse health effects, according to a report presented ... Committee provides advice to authorities about risk management ... assessed the health hazards from low-level electromagnetic fields ...
... Research Institute and Sea Lane Biotechnologies have solved the co-crystal ... in a unique way. The antibody recognizes the crucial structure ... though previously this structure had been thought too small for ... hit this precise spot by using just a small part ...
Cached Biology News:Rice to take part in $10.8 million study of hemoglobin toxicity 2Rice to take part in $10.8 million study of hemoglobin toxicity 3Mobile phones and wireless networks: No evidence of health risk found 2Mobile phones and wireless networks: No evidence of health risk found 3Mobile phones and wireless networks: No evidence of health risk found 4Flu antibody’s 'one-handed grab' may boost effort toward universal vaccine, new therapies 2Flu antibody’s 'one-handed grab' may boost effort toward universal vaccine, new therapies 3
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
WNV Core Antibody...
Biology Products: